Transcriptional Targets of the Vitamin D ₃ Receptor During Myeloid Cell Differentiation

The emergence of 1,25(OH)2D3 as a general inhibitor of cell proliferation and inducer of myeloid differentiation has renewed interest in this ligand as a potentially efficacious chemotherapeutic for several types of cancers, including leukemias, and solid tumors such as breast and prostate. This relatively new biology of vitamin D has also stimulated interest in the development of synthetic vitamin D compounds for a variety of clinical applications, especially cancer.